MYCN and neuroblastoma: Retinoic acid (RA), a derivative of vitamin A, is known to downregulate N-Myc and induce neuroblastoma differentiation 30–34, making it an FDA-approved therapy for increasing event-free survival in neuroblastoma patients 35.